SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 211 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.81 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $1,343,000 | +40.8% | 149,835 | 0.0% | 0.05% | +18.6% |
| Q1 2020 | $954,000 | -23.9% | 149,835 | 0.0% | 0.04% | -8.5% |
| Q4 2019 | $1,254,000 | -3.6% | 149,835 | +24.1% | 0.05% | -11.3% |
| Q2 2019 | $1,301,000 | -43.5% | 120,768 | -50.0% | 0.05% | -43.6% |
| Q1 2019 | $2,304,000 | -16.9% | 241,538 | 0.0% | 0.09% | -21.0% |
| Q4 2018 | $2,773,000 | -4.8% | 241,538 | +40.5% | 0.12% | +12.3% |
| Q3 2018 | $2,914,000 | +70.3% | 171,889 | +42.6% | 0.11% | +63.1% |
| Q2 2018 | $1,711,000 | +105.6% | 120,512 | +60.7% | 0.06% | +116.7% |
| Q2 2015 | $832,000 | -92.2% | 75,000 | -89.0% | 0.03% | -92.9% |
| Q1 2015 | $10,648,000 | +3.1% | 679,100 | 0.0% | 0.42% | -12.6% |
| Q4 2014 | $10,329,000 | +27.7% | 679,100 | -9.5% | 0.48% | +27.4% |
| Q3 2014 | $8,090,000 | +339.9% | 750,100 | +523.0% | 0.38% | +124.3% |
| Q2 2014 | $1,839,000 | +114.6% | 120,400 | +154.0% | 0.17% | +96.5% |
| Q1 2014 | $857,000 | – | 47,400 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Golden State Equity Partners | 154,360 | $897,000 | 0.45% |
| Rhenman & Partners Asset Management AB | 761,429 | $4,424,000 | 0.44% |
| Lombard Odier Asset Management (Switzerland) SA | 860,702 | $5,001,000 | 0.39% |
| WASATCH ADVISORS LP | 10,576,997 | $61,452,000 | 0.30% |
| Rokos Capital Management LLP | 977,663 | $5,861,000 | 0.27% |
| KLK CAPITAL MANAGEMENT LLC | 44,323 | $258,000 | 0.26% |
| Long Focus Capital Management, LLC | 340,000 | $1,975,000 | 0.25% |
| Vanguard Capital Wealth Advisors | 33,380 | $193,000 | 0.14% |
| Fort Sheridan Advisors LLC | 73,978 | $430,000 | 0.13% |
| Delphia (USA) Inc. | 20,983 | $122,000 | 0.09% |